Dubai: The Emirates Society of Haematology (ESH) has collaborated with Takeda Pharmaceuticals Company (“Takeda”), a global, values-based, R&D-driven biopharmaceutical company for the second consecutive year to ensure awareness around the rare forms of blood cancer including multiple myeloma and Hodgkin lymphoma. The partnership will see ESH collaborate with Takeda on developing effective mechanisms that will support widespread community awareness and help the medical community deliver the best patient outcomes.
According to Globocan 202 in the UAE, a five-year prevalence for multiple myeloma and Hodgkin lymphoma. are 173 and 339 per 100,000 persons. Multiple myeloma is a blood cancer formed when plasma cells, a type of white blood cell made in the bone marrow, become cancerous and grow out of control. These malignant plasma cells have the potential to affect many bones in the body, possibly resulting in compression fractures, lytic bone lesions and related pain. While multiple myeloma is a relatively rare disease, accounting for approximately one percent of cancers diagnosed worldwide, it is the second most common form of blood cancer.
Lymphoma is a general term for a group of cancers that originate in the lymphatic system. Hodgkin lymphoma is distinguished from other types of lymphoma by the presence of one characteristic type of cell, known as the Reed-Sternberg cell. Up to 30 percent of newly diagnosed Hodgkin lymphoma patients progress following frontline therapy depending on the stage of the disease. However, only 50 percent of patients with relapsed or refractory Hodgkin lymphoma achieve long-term remission with high-dose chemotherapy and an autologous stem cell transplant, a historically used treatment regimen, highlighting the need for successful treatments for previously untreated patients.
The Emirates Society of Haematology Board commented, “As a part of our mandate, the Society works to foster the specialty of Haematology by forming links with colleagues across the world, to improve the quality of care for patients. In honor of Blood Cancer Awareness Month celebrated in September, ESH, in collaboration with Takeda, our goal was to create and develop educational opportunities for our members and facilitate best clinical practice in this field for UAE physicians and make sure of scientific and medical knowledge available for all health care professionals in the UAE as well as our region”
Sherif Ibrahim, Medical Affairs Director, Takeda Middle East said, “As part of Takeda’s ongoing commitment to putting patients first, we strive to connect people navigating a cancer diagnosis, their caregivers and their healthcare providers with the support they seek. For the second consecutive year we are proud to partner with The Emirates Society of Haematology to improve community-level awareness of the various forms of cancer and to enable an ecosystem that achieves earlier diagnosis and can support paradigm-changing therapies that improve survival rates.”
This year’s campaign is also aligned with Takeda’s global Greater Than Cancer campaign that is helping raise awareness and educate the community on blood cancer types while engaging patients, caregivers, advocacy organizations and healthcare professionals.
About The Emirates Society of Haematology:
The Emirates Society of Haematology works to foster the specialty of Haematology in the UAE and form links with colleagues in the UAE, regional countries, and the international Haematology community. The attention is on improvement in the quality of care for patients suffering from conditions prevalent throughout the UAE. There are now approximately 90 members and associate members from all fields of Haematology. Regular meetings of the society are held in different locations to provide a regular forum for professional interchange amongst all medically qualified practitioners who are trainees or specialists in Haematology.
About Takeda Pharmaceutical Company Limited:
Takeda Pharmaceutical Company Limited is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to bringing Better Health and a Brighter Future to patients by translating science into highly-innovative medicines. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Diseases, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries.